The growing popularity of direct-to-consumer medical lab testing

The surge in direct-to-consumer (DTC), self-initiated medical lab testing represents a significant shift in American healthcare, driven by a growing appetite for "proactive" wellness and increasing skepticism toward the traditional medical establishment (NYTimes). Companies like the startup Function Health, as well as major players including Quest Diagnostics, Hims & Hers, and Oura, are capitalizing on this trend by offering extensive testing panels -- often screening for over 100 biomarkers -- that bypass the standard doctor’s visit and insurance requirements. This "self-serve" model appeals particularly to consumers who feel ignored by physicians or wish to investigate chronic, undiagnosed symptoms through a data-driven lens, often with the goal of avoiding pharmaceutical interventions in favor of lifestyle changes. However, this explosion of data has ignited a debate within the medical community: while proponents argue that broad testing empowers patients to identify early warning signs of illness, critics worry that subjecting healthy individuals to "fishing expeditions" creates a high risk of false positives, unnecessary anxiety, and costly, unguided medical interventions.

The most robust evidence supporting the benefits of this direct-to-consumer (DTC) lab testing approach lies in targeted, clinically actionable diagnostics rather than broad “wellness” panels. For example, randomized controlled trials demonstrate that at-home testing for sexually transmitted infections (STIs) and HIV significantly increases screening uptake by eliminating barriers like stigma and inconvenience, with the vast majority of positive cases moving forward to confirmatory testing and treatment (such as a 92% linkage rate for HIV). Similarly, for chronic disease management, providing at-home kits for markers like HbA1c enables patients with type 2 diabetes to monitor their condition more consistently, leading to clinically meaningful improvements in blood sugar control. In addition to these health outcomes, the DTC model provides economic benefits by offering transparent, lower-cost alternatives to traditional hospital labs for uninsured or underinsured patients. Finally, consumers often report significant psychological benefits, citing a sense of empowerment, and the motivation to take a proactive role in their personal health management.

On the other hand, there is evidence that DTC testing can harm consumers through risks of false positives, overdiagnosis, and unsupervised medical interventions. Because standard lab references have a built-in false positive rate of roughly 5%, broad "wellness panels" that test dozens or hundreds of biomarkers almost guarantee that users will receive out-of-range results purely by chance (multiple testing problem). These false alarms frequently trigger psychological distress, financial burdens, and invasive, risky follow-up procedures like unnecessary biopsies. Furthermore, bypassing a physician's initial clinical triage leaves patients without the necessary context to interpret complex data, making them vulnerable to "science-ploitation", the use of scientifically unreliable metrics such as unproven food sensitivity tests, and even unproven and potentially physically damaging treatments.

A complex patchwork of federal and state regulations governs DTC medical testing with the focus primarily on test accuracy and privacy rather than medical necessity. At the federal level, the Centers for Medicare & Medicaid Services (CMS) enforces CLIA (Clinical Laboratory Improvement Amendments) standards to ensure that laboratories produce analytically valid and accurate results, but does not evaluate clinical usefulness. Side-by-side, the FDA also regulates medical devices and test kits, which includes the clinical validity of the test. The distinction between CMS and FDA oversight is that CLIA ensures that the biomarker is measured accurately while the FDA is also concerned that the biomarker can help diagnose the particular medical condition. This distinction is relevant because many DTC companies circumvent FDA review by offering  proprietary "Laboratory Developed Tests" (LDTs) which are subject to CMS/CLIA but not FDA regulations, or by categorizing their services as low-risk "general wellness" which also exempts them from FDA review. 

Finally, because state laws dictate who can legally order a lab test, many national DTC companies operate using third-party telehealth networks. In this workaround, a remote physician formally orders the tests to satisfy state requirements, technically providing a medical safeguard but lacking the personalized oversight and clinical context of a traditional doctor-patient relationship established through in-person visits.

As of yet, there are no dominant players in the new lab testing market, but rather a diverse ecosystem of traditional diagnostic giants, consumer-first digital health "unicorns," and expanding telehealth platforms. First are the "Big Two" medical diagnostics incumbents, Labcorp (via Labcorp OnDemand) and Quest Diagnostics (via QuestHealth.com); these multibillion-dollar powerhouses not only offer hundreds of tests directly to patients but also provide the essential backend blood-draw infrastructure for many of their competitors. Next are the highly valued digital health companies like Everly Health (Everlywell) and LetsGetChecked, which have built billion-dollar brands primarily around convenient at-home test kits. A rapidly growing sub-sector includes "wellness biomarker subscription" startups, highlighted by Function Health (Figure 1) alongside optimization-focused competitors like InsideTracker. Finally, there are the major telehealth and wearable integrators such as Hims & Hers, Ro, Whoop, and Oura, which are embedding diagnostic testing into their existing ecosystems.

The catalog of services offered by these companies range from individual at-home collection kits to comprehensive, subscription-based "whole-body" panels. Quest Diagnostics and Labcorp allow consumers to bypass a standard doctor's visit by ordering from a menu of hundreds of tests online, using independent physician networks to approve the orders for in-person blood draws. The digital health startups (e.g. Everlywell and LetsGetChecked) specialize in convenient, mail-in kits for specific concerns like food sensitivities or sexual health, often paired with telehealth follow-ups, while wellness brands like Function Health and InsideTracker offer expensive, extensive biomarker subscriptions that use AI to provide personalized diet, lifestyle, and longevity recommendations. Additionally, telehealth platforms like Hims & Hers and wearable tech companies like Oura now integrate lab testing directly into their apps to offer seamless prescription pathways or correlate blood data with sleep and fitness metrics. 

To promote these diverse products, the industry relies on messaging centered around empowerment, convenience, and optimization. Traditional labs emphasize privacy and "hospital-grade" clinical trust, while wellness-focused startups lean into consumer frustration with the standard healthcare system, using proactive slogans like Function’s “Ignored by most. Tested by us.” Across the board, these companies market their services not merely as diagnostic tools, but as a way to validate dismissed symptoms, uncover the "root causes" of illness, and put patients in direct control of their health data without needing permission from their primary care physician.

Not surprisingly the medical community has responded to these marketing claims with caution, but also some degree of conditional support. Medical experts acknowledge that easier access to testing can be valuable in select, high-impact situations, but argue that many promotional messages can overpromise benefits while underplaying predictable downsides. The American Medical Association, for example, warns that self-directed/direct-access testing can be misinterpreted, may skirt regulatory requirements, and often lacks appropriate diagnostic and counseling practices, and it has called for DTC testing to be delivered by physician-led teams in CLIA-certified facilities. Laboratory-medicine experts similarly emphasize that DTC testing is safest when limited to clinically relevant tests paired with clear, accessible explanations of purpose, risks, appropriate use, and results interpretation. A BMJ Commentary reinforces this critique, arguing that DTC testing often occurs outside traditional healthcare protections and that aggressive marketing can mislead consumers, increasing the risk of psychological, physical, and financial harms from false alarms, overtesting, and unnecessary follow-up.

In particular, physicians warn that screening asymptomatic individuals for hundreds of biomarkers is essentially a fishing expedition" that is likely to produce "abnormal" results due to natural, daily biological fluctuations, as well as false positives from the multiple testing issue described above. In this manner, healthy patients may become trapped in a cycle of "incidentalomas" -- harmless anomalies that trigger severe anxiety and lead to invasive, costly follow-up procedures like biopsies.

In terms of navigating this new landscape of accessible testing options, consumers should approach the process strategically by prioritizing targeted tests for specific concerns over broad "mega-panels" or scientifically dubious screens (like IgG food sensitivity tests) that can generate anxiety-inducing false positives. Before ordering, it is essential to verify that the company uses CLIA-certified laboratories, carefully review privacy policies regarding health data sharing, and opt for services that provide access to real medical professionals rather than relying strictly on AI-generated summaries. When interpreting results, users should remember that mild abnormalities are often normal biological fluctuations and lack necessary clinical context, so a single out-of-range number should not cause immediate panic. Most importantly, consumers should never make drastic medical or dietary changes based solely on a DTC test; instead, they should share concerning results with their primary care physician, who can evaluate the data alongside their medical history and order reliable confirmatory testing before initiating any treatment. 

To summarize, yes DTC tests can provide valuable information that complement traditional health monitoring, but no you should not act on this information without consulting with your doctor who is familiar with your total health situation.

Figure 1. The direct-to-consumer (DTC) health testing company Function Health advertises 160+ lab tests (twice per year) detecting 1000+ conditions for $365 per year (https://www.functionhealth.com/).